Why the study?
Does liposomal doxorubicin improve outcomes in patients with primary cardiac angiosarcoma?
Does liposomal doxorubicin improve outcomes in patients with primary cardiac angiosarcoma?
Liposomal doxorubicin may be a useful therapeutic option for primary cardiac angiosarcoma, a rare tumor with a typically dismal prognosis.
No takes yet. Share an insight, caveat, or question.
Should not change practice; hypothesis-generating for this rare malignancy.
Kodali et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: